As the number of cancer survivors has increased significantly over the last decades due to
aging of population and development of effective cancer therapies, side effects from cancer …

Although cardiovascular toxicity from traditional chemotherapies has been well recognized
for decades, the recent explosion of effective novel targeted cancer therapies with …

Recent therapeutic advances have significantly improved the short‐and long‐term survival
rates in patients with heart disease and cancer. Survival in cancer patients may, however, be …

Baseline risk stratification for cardiotoxicity is a crucial component of the cardio-oncology
service. 1, 2 Guideline statements recommend risk assessment based on a number of …

The advancement in therapy has provided a dramatic improvement in the rate of recovery
among cancer patients. However, this improved survival is also associated with enhanced …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Cardio-oncology is an emerging field that seeks to enhance quality of life and longevity of
cancer survivors. It is pertinent for clinicians to understand the cellular mechanisms of …

Abstract In the United States, the lifetime risk of a cancer diagnosis is nearly 40%; in 2016,
that represents almost 1.6 million new patients, and despite advances in early diagnosis and …

The quest of defeating cancer and improving prognosis in survivors has generated
remarkable strides forward in research and have advanced the development of new …

Background: Cardiotoxicity remains an important adverse reaction of chemotherapy used in
the treatment of breast cancer, leading to increased morbidity and mortality. Data Sources …